| 论文题目： | Human Clinical-Grade Parthenogenetic ESC-Derived Dopaminergic Neurons？Recover Locomotive Defects of Nonhuman Primate Models of？Parkinson's Disease |
| 论文题目英文： | |
| 作者： | 王昱凯①，朱宛宛①，吴孟华①，吴一卉，刘征鑫，Ling-Min Liang，盛超，郝捷，王柳，李伟，周琪*，胡宝洋* |
| 论文出处： | |
| 年： | 2018 |
| 卷： | |
| 期： | DOI: 10.1016/j.stemcr.2018.05.010 |
| 页： | |
| 联系作者： | 周琪，胡宝洋 |
| 发表期刊： | Stem Cell Reports |
| ISSN： | |
| 第一作者所在部门： | |
| 收录类别： | |
| 论文连接 | https://www.sciencedirect.com/science/article/pii/S2213671118302273 |
| 影响因子： | |
| 摘要: | Clinical application of stem cell derivatives requires clinical-grade cells and sufficient preclinical proof of safety and efficacy, preferably in primates. We previously successfully established a clinical-grade human parthenogenetic embryonic stem cell (hPESC) line, but the suitability of its subtype-specific progenies for therapy is not clear. Here, we compared the function of clinical-grade hPESC-derived midbrain dopaminergic (DA) neurons in two canonical protocols in a primate Parkinson's disease (PD) model. We found that the grafts did not form tumors and produced variable but apparent behavioral improvement for at least 24 months in most monkeys in both groups. In addition, a slight DA increase in the striatum correlates with significant functional improvement. These results demonstrated that clinical-grade hPESCs can serve as a reliable source of cells for PD treatment. Our proof-of-concept findings provide preclinical data for China's first ESC-based phase I/IIa clinical study of PD (ClinicalTrials.gov number NCT03119636). |
| 英文摘要： | |
| 外单位作者单位： |